ANDA 209086, held by Actavis Labs. Ingenol Mebutate.
As of Nov 16, 2026, ANDA 209086 (Ingenol Mebutate), held by Actavis Labs, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2018 | Original application | Tentative approval |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ingenol Mebutate0.05% ยท gel; topical | Ingenol Mebutate | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters